• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Nuvation Bio (NUVB)

Sell: $2.16|Buy: $2.28|Change: 0.07 (3.21%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.

Address




Website

https://www.nuvationbio.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Nuvation Bio Inc First Quarter Earnings Conference Call for 20262026-05-07T16:30:00
Nuvation Bio Inc First Quarter Earnings Results for 20262026-05-07T00:00:00
Nuvation Bio Inc Fourth Quarter Earnings Results for 20252026-03-06T00:00:00
Nuvation Bio Inc Annual Report for 20252026-03-06T00:00:00
Nuvation Bio Inc Third Quarter Earnings Results for 20252025-11-06T00:00:00
Nuvation Bio Inc Second Quarter Earnings Results for 20252025-08-05T00:00:00
Nuvation Bio Inc Annual General Meeting for 20252025-07-10T11:00:00
Nuvation Bio Inc First Quarter Earnings Conference Call for 20252025-05-07T16:30:00
Nuvation Bio Inc First Quarter Earnings Result for 20252025-05-07T00:00:00

Previous key dates

NameKey Date
Nuvation Bio Inc First Quarter Earnings Conference Call for 20252025-05-07T16:30:00
Nuvation Bio Inc First Quarter Earnings Result for 20252025-05-07T00:00:00
Jones Healthcare and Technology Innovation Conference2025-04-09T10:00:00
Nuvation Bio Inc Fourth Quarter Earnings Results for 20242025-03-06T00:00:00
Nuvation Bio Inc Annual Report for 20242025-03-06T00:00:00
TD Cowen 45th Annual Health Care Conference2025-03-03T15:10:00
43rd Annual J.P. Morgan Healthcare Conference2025-01-13T09:00:00
7th Annual Evercore ISI HealthCONx Conference 20242024-12-04T09:10:00
Jefferies London Healthcare Conference2024-11-19T03:30:00
Nuvation Bio Inc Third Quarter Earnings Results for 20242024-11-06T00:00:00
Cantor Global Healthcare Conference2024-09-19T09:45:00
Nuvation Bio Inc Second Quarter Earnings Results for 20242024-08-05T00:00:00
Nuvation Bio Inc Annual General Meeting for 20242024-07-10T11:00:00
Nuvation Bio will participate at Jefferies Global Healthcare Conference2024-06-05T13:30:00
Nuvation Bio Inc First Quarter Earnings Results for 20242024-05-14T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2025 AJ Bell. All rights reserved.